Production (Stage)
Arcadia Biosciences, Inc.
RKDA
$4.28
$0.102.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.65% | 9.60% | 0.79% | -9.81% | -19.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.65% | 9.60% | 0.79% | -9.81% | -19.72% |
| Cost of Revenue | 55.56% | 11.60% | -25.39% | -44.03% | -47.54% |
| Gross Profit | -7.41% | 7.19% | 44.37% | 71.55% | 39.87% |
| SG&A Expenses | 21.07% | -0.67% | -25.41% | -40.50% | -47.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.64% | 1.81% | -24.93% | -40.79% | -47.44% |
| Operating Income | -33.35% | 2.87% | 36.77% | 52.78% | 58.99% |
| Income Before Tax | -167.73% | 39.59% | 92.65% | 98.43% | 107.30% |
| Income Tax Expenses | 0.00% | 0.00% | -50.00% | -53.33% | -42.86% |
| Earnings from Continuing Operations | -168.93% | 39.54% | 92.59% | 98.37% | 107.24% |
| Earnings from Discontinued Operations | 84.70% | 60.25% | 8.90% | -54.97% | -324.50% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -100.00% | -95.61% |
| Net Income | 71.28% | 49.66% | 62.09% | 56.73% | 65.37% |
| EBIT | -33.35% | 2.87% | 36.77% | 52.78% | 58.99% |
| EBITDA | -38.89% | 0.62% | 36.30% | 53.48% | 59.85% |
| EPS Basic | 71.33% | 63.75% | 76.80% | 76.51% | 81.99% |
| Normalized Basic EPS | -544.28% | 33.50% | 70.74% | 80.09% | 105.20% |
| EPS Diluted | 71.31% | 63.72% | 76.78% | 76.49% | 81.98% |
| Normalized Diluted EPS | -544.28% | 33.50% | 70.74% | 80.09% | 105.20% |
| Average Basic Shares Outstanding | 0.30% | 10.30% | 28.05% | 55.13% | 101.02% |
| Average Diluted Shares Outstanding | 0.30% | 10.30% | 28.05% | 55.13% | 101.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |